Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster

Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale...

Related Keywords

New Jersey ,United States ,Japan ,South San Francisco ,California ,Bristol Myers Squibb ,Fabian Gerlinghaus ,Lynelleb Hoch ,Cellare Technology Adoption Partnership ,Cell Therapy Organization ,Youtube ,Linkedin ,Twitter ,Manufacturing Organization ,Exchange Commission ,Facebook ,Instagram ,Integrated Development ,Cell Shuttle ,Cell Shuttles ,Cellare Smart Factories ,Bristol Myers ,Smart Factories ,Myers Squibb ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,